Evidence level: B
体质评分改善,是否必须经过”目标菌在肠道站稳脚跟”这一站?如果菌没定植、分也照涨,那”定植”就不是疗效的必经之路,而是两条平行通道中的一条。
正文
中医体质学说认为,痰湿、湿热、阳虚等偏颇体质对应不同的生理失衡状态;现代研究进一步发现,九种体质与肠道菌群结构存在可重复的关联。于是”菌群干预改善偏颇体质”成了一个自然的假设链:给菌 → 菌定植 → 体质评分改善。这条链里藏着两个可分离的环节——干预是否让菌”住下来”(定植),以及”住下来”是否是评分改善的必要中介。第二个问题,恰恰是几乎没人直接测过的。
先说”定植”这站本身有多不牢靠。魏茨曼科学研究所的 Zmora 团队用 15 名受试者的黏膜活检发现,经验性益生菌摄入后,只有约一半人能在黏膜上检出目标菌株,且定植与否可由基线宿主与菌群特征预测(PMID 30193112)。也就是说,”吃进去”和”住下来”之间隔着一道个体化的黏膜定植抵抗——对定居者有效的一瓶菌,对抵抗者可能只是过路客。
再把镜头拉长到粪菌移植(FMT)。Podlesny 等对 14 个 FMT 试验、250 余人的宏基因组整合分析显示,供体菌株定植率与临床成功显著正相关(P=0.017),但定植率在应答者与非应答者之间并无差异的疾病同样存在(IBD、黑色素瘤队列;PMID 35931074)。Osaki 等在 IBD 患者中发现,UC 应答者移植后 Clostridium cluster XIVa 计数升高、供体 Fusicatenibacter saccharivorans 计数与 8 周缓解显著相关(PMID 35111551)——这支持”定植-应答”关联,但关联不等于中介。
真正的反例来自一个最干净的实验:Andresen 等的 443 人多中心双盲 RCT 中,热灭活的两歧双歧杆菌 MIMBb75(死菌,已不可能定植)仍将 IBS 症状复合终点应答率从 19% 提升到 34%(RR 1.7,P=0.0007;PMID 32277872)。死菌有效,意味着效应通道至少有一部分不依赖定植——可能是细胞壁成分与免疫受体的直接互作,或屏障功能的非特异性强化(PMID 38195358 对 FMT 机制的解构也指出,疗效更可能来自功能网络恢复而非单纯的菌株驻留)。
这就构成了裁决的必要性:若”定植必要论”为真,死菌组应无效;若”非定植通道”为真,抵抗者(无法定植的人)仍应获益。两者可以同时为真——而各自贡献多大,正是中介分析要回答的。近年两步中介孟德尔随机化已把”比例中介”做成了可量化的输出,例如菌群经免疫细胞影响慢性 GVHD 的中介比例可精确到 4.2% 与 9.5%(PMID 40316245),这套”总效应-间接效应拆分”的语法完全可移植到体质-菌群干预上。
裁决设计(三臂 RCT + 中介模型):
– 分组:同一种体质人群(如痰湿质)随机分三臂——活菌组 / 热灭活菌组 / 安慰剂组,干预 8 周,干预中、干预后 2 个时点测粪便与(可行时)黏膜目标菌定量;
– 结局:体质评分(CCMQ 或简化量表)复评;
– 中介分析:以定植率为中介变量,构建两条路径——模型 A(定植→评分改善的间接路径)与模型 B(干预→评分改善的直接路径,绕过定植),用结构方程 SEM 加置换检验比较间接效应占比;Baron-Kenny 四步法作稳健性对照;
– 分层对照:按基线定植潜能(参照 PMID 30193112 的预测特征)把受试者分为”定居者/抵抗者”,检验交互项——若抵抗者在活菌组仍获益且效应可被模型 B 解释,则非定植通道坐实。
裁决判读表:
| 观测模式 | 判定 |
|---|---|
| 活菌组与死菌组都有效,定植者与抵抗者均获益 | 非定植通道为主,定植中介比例小 |
| 活菌组有效、死菌组无效,且仅定居者获益 | 定植是必要中介 |
| 活菌组有效但抵抗者获益小于定居者 | 双通道并存,中介比例为部分中介 |
| 两组均无效 | 干预本身无效,与定植无关 |
无论哪种结果,都直接回答了”调理体质,菌到底要不要先住下来”这个可落地的问题——对抵抗者而言,若非定植通道成立,死菌/后生元制剂就是更稳、更便宜、更少个体差异的选择。
证据与局限
已验证: 定植存在个体差异且可预测(PMID 30193112);FMT 定植率与临床成功正相关(PMID 35931074);热灭活菌 RCT 有效,证明存在不依赖定植的效应通道(PMID 32277872)。
部分验证: 定植-应答关联在部分疾病(IBD)中不随应答分组差异(PMID 35931074);应答者特定菌属变化与缓解相关(PMID 35111551)。
待验证: 体质评分改善的”定植中介比例”尚无直接研究——本裁决设计即针对此空白;死菌通道的具体分子机制(细胞壁成分、代谢物、免疫受体互作)需机制实验。
相关阅读
证据等级: B
参考文献: PMID 30193112, PMID 35931074, PMID 32277872, PMID 35111551, PMID 38195358, PMID 40316245
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
Does Effective Gut Microbiota Modulation Require Prior Colonization? A Design for Testing the \”Colonization Mediator\” Hypothesis
Evidence level: B
Does improvement in constitution scores necessitate the station of “target bacteria establishing a foothold in the gut”? If scores rise without engraftment, then “engraftment” is not a mandatory pathway to efficacy but merely one of two parallel channels.
Main Text
Traditional TCM constitution theory posits that imbalanced constitutions—such as phlegm-dampness, damp-heat, or yang deficiency—correspond to distinct physiological dysbalances; modern research further identifies reproducible associations between the nine constitutions and gut microbiome structure. Consequently, “microbiome intervention improves imbalanced constitution” forms a natural hypothesis chain: Introduce Bacteria → Bacterial Engraftment → Constitution Score Improvement. This chain conceals two separable links: whether intervention allows bacteria to “settle” (engraft), and whether settling is a necessary mediator for score improvement. The second question remains largely unmeasured directly.
First, consider the instability of the “engraftment” link itself. The Zmora team at the Weizmann Institute of Science found via mucosal biopsies in 15 subjects that empirical probiotic intake resulted in target strain detection on the mucosa in only about half of individuals, and whether engraftment occurs can be predicted by baseline host and microbiome characteristics (PMID 30193112). Thus, “ingestion” and “settling” are separated by an individualized mucosal engraftment resistance—a strain effective for settlers may merely be a passer-by for resisters.
Zooming out to Fecal Microbiota Transplantation (FMT), a meta-genomic integration analysis by Podlesny et al. across 14 FMT trials and over 250 individuals showed a significant positive correlation between donor strain engraftment rates and clinical success (P=0.017), yet diseases exist where engraftment rates show no difference between responders and non-responders (IBD, melanoma cohorts; PMID 35931074). Osaki et al. found in IBD patients that UC responders showed increased Clostridium cluster XIVa counts post-transplant, and donor Fusicatenibacter saccharivorans counts correlated significantly with 8-week remission (PMID 35111551)—supporting an “engraftment-response” association, but association does not equal mediation.
The true counterexample arises from the cleanest experiment: in Andresen et al.’s 443-subject multicenter double-blind RCT, heat-killed Bifidobacterium longum MIMBb75 (dead bacteria, incapable of engraftment) still increased the composite IBS symptom response rate from 19% to 34% (RR 1.7, P=0.0007; PMID 32277872). Dead bacteria efficacy implies at least one effect channel is independent of engraftment—possibly direct interaction between cell wall components and immune receptors, or non-specific reinforcement of barrier function (PMID 38195358 also deconstructs FMT mechanisms, suggesting efficacy likely stems from functional network restoration rather than mere strain residence).
This establishes the necessity of adjudication: if “engraftment-necessity” is true, the dead-bacteria group should be ineffective; if “non-engraftment channel” is true, resisters (those unable to engraft) should still benefit. Both can be true—while the relative contribution of each is precisely what mediator analysis must answer. Recent two-step mediator Mendelian randomization has turned “proportion mediation” into a quantifiable output; for instance, the proportion of microbiome effects mediated via immune cells in chronic GVHD can be precise to 4.2% and 9.5% (PMID 40316245). This “total effect-indirect effect splitting” syntax is fully portable to constitution-microbiome intervention.
Adjudication Design (Three-arm RCT + Mediator Model):
– Grouping: Randomize a single constitution population (e.g., phlegm-dampness) into three arms—live bacteria / heat-killed bacteria / placebo—intervene for 8 weeks, measure fecal and (if feasible) mucosal target bacteria quantification at intervention midpoint and 2 post-intervention timepoints;
– Outcomes: Re-evaluate constitution scores (CCMQ or simplified scale);
– Mediator Analysis: Use engraftment rate as the mediator variable, construct two paths—Model A (indirect path: Engraftment → Score Improvement) and Model B (direct path: Intervention → Score Improvement bypassing Engraftment)—compare indirect effect proportions using structural equation modeling (SEM) with permutation tests; apply Baron-Kenny four-step method for robustness control;
– Stratified Control: Stratify subjects into “settlers/resisters” based on baseline engraftment potential (referencing predictive features in PMID 30193112), test interaction terms—if resisters benefit in the live-bacteria arm and effects can be explained by Model B, the non-engraftment channel is confirmed.
Adjudication Interpretation Table:
| Observation Pattern | Judgment |
|---|---|
| Both live and dead groups effective; both settlers and resisters benefit | Non-engraftment channel dominant, small engraftment mediation proportion |
| Live group effective, dead group ineffective; only settlers benefit | Engraftment is necessary mediator |
| Live group effective but resisters benefit less than settlers | Dual channels coexist, partial mediation proportion |
| Both groups ineffective | Intervention itself ineffective, unrelated to engraftment |
Regardless of the outcome, this directly answers the actionable question: “Does adjusting constitution require bacteria to first settle?” For resisters, if the non-engraftment channel holds, dead-bacteria or postbiotic formulations offer a more stable, cheaper, and less individualized-difference-prone choice.
Evidence and Limitations
Verified: Individual differences in engraftment exist and are predictable (PMID 30193112); FMT engraftment rates correlate positively with clinical success (PMID 35931074); heat-killed bacteria RCT efficacy proves existence of an effect channel independent of engraftment (PMID 32277872).
Partially Verified: Engraftment-response associations in certain diseases (IBD) do not vary by responder grouping (PMID 35931074); specific genus changes in responders correlate with remission (PMID 35111551).
To Be Verified: “Engraftment mediation proportion” for constitution score improvement lacks direct research—this adjudication design targets this gap; specific molecular mechanisms of the dead-bacteria channel (cell wall components, metabolites, immune receptor interactions) require mechanistic experiments.
Related Reading
- Responder Stratification in Constitution × Microbiome Intervention: Why Some Use One Bottle, Others Don’t
- Cross-Species Engraftment Fidelity Adjudication for Constitution FMT: Transferred Does Not Mean Fully Transferred
- Research Pool: Biological Frequency Codes
Evidence Level: B
References: PMID 30193112, PMID 35931074, PMID 32277872, PMID 35111551, PMID 38195358, PMID 40316245
Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.
Leave a Reply